{"organizations": [], "uuid": "8a3c89773027740bf9804b506102011f72044ffe", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-valeant-reports-q1-loss-per-share/brief-valeant-reports-q1-loss-per-share-7-68-idUSASC0A0E8", "country": "US", "domain_rank": 408, "title": "BRIEF-Valeant Reports Q1 Loss Per Share $7.68", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T14:16:00.000+03:00", "replies_count": 0, "uuid": "8a3c89773027740bf9804b506102011f72044ffe"}, "author": "", "url": "https://www.reuters.com/article/brief-valeant-reports-q1-loss-per-share/brief-valeant-reports-q1-loss-per-share-7-68-idUSASC0A0E8", "ord_in_thread": 0, "title": "BRIEF-Valeant Reports Q1 Loss Per Share $7.68", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "valeant pharmaceuticals international inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8, 2018 / 11:20 AM / Updated 13 minutes ago BRIEF-Valeant Reports Q1 Loss Per Share $7.68 Reuters Staff\nMay 8 (Reuters) - Valeant Pharmaceuticals International Inc :\n* VALEANT ANNOUNCES FIRST-QUARTER 2018 RESULTS AND RAISES REVENUE AND ADJUSTED EBITDA (NON-GAAP) GUIDANCE\n* Q1 REVENUE $1.995 BILLION VERSUS I/B/E/S VIEW $1.94 BILLION * Q1 LOSS PER SHARE $7.68\n* Q1 EARNINGS PER SHARE VIEW $0.59 — THOMSON REUTERS I/B/E/S\n* VALEANT - COMPANY’S NAME WILL CHANGE TO BAUSCH HEALTH COMPANIES INC. IN JULY 2018\n* VALEANT SEES 2018 FULL-YEAR REVENUES IN RANGE OF $8.15 - $8.35 BILLION\n* VALEANT - REPAID APPROXIMATELY $280 MILLION OF DEBT WITH CASH ON HAND IN Q1 OF 2018\n* VALEANT SEES 2018 ADJUSTED EBITDA (NON-GAAP) IN RANGE OF $3.15 - $3.30 BILLION\n* QTRLY ADJUSTED NET INCOME ATTRIBUTABLE TO VALEANT PHARMACEUTICALS INTERNATIONAL INC $312 MILLION\n* VALEANT - GOODWILL IMPAIRMENT CHARGES OF $2.213 BILLION IN QUARTER RELATED TO SALIX AND ORTHO DERMATOLOGICS BUSINESSES Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-08T14:16:00.000+03:00", "crawled": "2018-05-08T14:35:39.014+03:00", "highlightTitle": ""}